Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2025-11-21 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
DISCLOSEABLE TRANSACTION ISSUE OF EXCHANGEABLE PREFERENCE SHARES BY A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Luye Pharma Group Ltd. regarding a 'Disclosable Transaction' involving the issuance of exchangeable preference shares by a subsidiary. It details the subscription agreement, listing rule implications, and the nature of the transaction (a deemed disposal of equity interest). This fits the definition of a corporate announcement regarding financing and capital structure changes, which is classified as a Capital/Financing Update (CAP).
2025-11-21 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 95% confidence The document is a 'Positive Profit Alert' issued by Majestic Dragon AeroTech Holdings Limited. It provides preliminary financial expectations for the six months ended 30 September 2025, highlighting a turnaround from a loss to a profit. According to the filing definitions, an initial announcement of quarterly/periodical financial results (key highlights only) is classified as an Earnings Release (ER). Although it mentions the upcoming publication of the full interim results, the document itself serves as the primary announcement of the financial performance for the period. H1 2025
2025-11-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
Regulatory Filings Classification · 85% confidence The document is a statutory monthly return (Form FF301) submitted by a Hong Kong equity issuer under Chapter 19B of the HKEX Listing Rules, detailing movements in authorised share capital, issued shares, convertibles, etc. This is a regulatory compliance filing to the exchange, not an earnings release, capital-raising announcement, or dividend notice, nor is it merely an announcement of a report publication. No specific category (e.g., SHA, POS) covers this periodic share movement return, so it falls under the catch-all “Regulatory Filings” category (RNS).
2025-11-05 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 85% confidence The document is a standard Hong Kong Exchange Listing Rule monthly return (Form FF301) detailing movements in authorized/registered share capital, issued shares, share options, and confirmations under Main Board/GEM Rules. It is a regulatory submission rather than a financial report, announcement of dividends or capital raising event, or transcript/presentation. It does not fit any specific category such as Share Issue/Capital Change (which covers individual announcements of new issues or stock splits) or Transaction in Own Shares. Therefore, it falls under the fallback category for miscellaneous regulatory filings.
2025-11-03 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 80% confidence The document is a notice of a Board meeting to approve interim results and potential dividend, rather than the actual interim report or a change in board composition. It does not fit earnings release (ER) since no results are published, nor management change (MANG), or dividend notice (DIV). Therefore, it defaults to a general Regulatory Filing announcement (RNS).
2025-11-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Share Issue/Capital Change Classification · 90% confidence The document is a mandatory monthly return (Form FF301) filed with the Hong Kong Stock Exchange detailing movements in authorised/issued share capital, share issues, convertibles, and related confirmations. It is not a financial report or earnings release, nor simply an announcement of a report. It specifically reports share capital changes and issuance activity under the Exchange Listing Rules, matching the description for “Share Issue/Capital Change” (Code: SHA).
2025-10-02 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.